Joe Gomes

Brice Thomas

Paul Strigler

- **Sonoma Biotherapeutics** announced **positive interim safety and efficacy data** from its **Phase 1 REGULATE-RA clinical trial** for **SBT-77-7101** in patients with **refractory rheumatoid arthritis (RA)**.  **[1106838_4f4fac57cefe4430969d7d216387d3e5_0]** 
- The study, involving **6 participants**, demonstrated a **favorable safety profile** with **no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS)**.  **[1106838_4f4fac57cefe4430969d7d216387d3e5_0]** 
- **4 out of 6 participants (67%)** experienced a **≥50% reduction in swollen and tender joint counts** from baseline by Week 4.  **[1106838_4f4fac57cefe4430969d7d216387d3e5_1]** 
- **5 out of 6 participants (83%)** showed a reduction in both DAS28-CRP and CDAI, with **4 out of 6 participants (67%)** achieving a reduction of DAS28-CRP score ≥2 and a reduction of CDAI ≥25.5.  **[1106838_4f4fac57cefe4430969d7d216387d3e5_1]** 
- Participants in **Cohort 2 (higher dose)** demonstrated **deeper and more consistent reductions** in joint counts, with all Cohort 2 participants showing **clinically meaningful improvements** by Week 4, and one participant demonstrating a **durable response through Week 24**.  **[1106838_4f4fac57cefe4430969d7d216387d3e5_1]**

Sonnet BioTherapeutics Holdings (SONN)